机构地区:[1]上海中医药大学附属光华医院关节内科,200052 [2]上海市中医药研究院中西医结合关节炎研究所,200052 [3]四川省绵阳市中医院风湿病科,621000 [4]重庆市第九人民医院风湿免疫科,400700 [5]上海中医药大学附属市中医医院风湿病科,200071 [6]上海中医药大学附属岳阳中西医结合医院风湿科,200437 [7]陆军军医大学第一附属医院中医与风湿免疫科,重庆400038 [8]上海中医药大学附属龙华医院风湿病科,200032 [9]辽宁中医药大学附属医院风湿科,沈阳110000 [10]云南省中医院风湿病科,昆明650021 [11]上海交通大学附属第一人民医院中医科,200080 [12]上海中医药大学药物临床研究中心,201203
出 处:《中华风湿病学杂志》2021年第5期307-315,共9页Chinese Journal of Rheumatology
基 金:国家科学自然基金面上项目(81774114);上海市中西医临床协作试点建设项目(ZY(2018-2020)-FWTX-1010);上海市中医专科联盟建设项目(ZY(2018-2020)-FWTX-4017)。
摘 要:目的本研究通过RA真实世界的大规模研究旨在比较中国RA血清阳性和血清阴性患者临床特征和预后。方法纳入2015年9月至2020年1月于全国10家医院就诊的符合1987年ACR分类标准或2010年ACR/ELUAR RA分类标准的RA患者。根据血清学状态,将患者分为4个亚组[RF(-)抗CCP抗体(-)、RF(+)抗CCP抗体(+)、RF(+)抗CCP抗体(-)、RF(-)抗CCP抗体(+)],并比较疾病特征和治疗反应。符合正态分布的计量资料采用单因素方差分析,不符合正态分布的采用Kruskal-Wallis H检验,各组内治疗前后比较符合正态分布采用配对t检验,不符合正态分布的采用配对秩和检验;计数资料采用χ^(2)检验。结果①共纳入患者2461例,其中RF(+)抗CCP抗体(+)患者1813例(73.67%),RF(+)抗CCP抗体(-)患者129例(5.24%),RF(-)抗CCP抗体(-)患者245例(9.96%),RF(-)抗CCP抗体(+)患者274例(11.13%)。②无论抗CCP抗体是否阳性,RF(+)患者发病早[RF(-)抗CCP抗体(-)(51±14)岁,RF(-)抗CCP抗体(+)(50±15)岁,RF(+)抗CCP抗体(+)(48±14)岁,RF(+)抗CCP抗体(-)(48±13)岁,F=3.003,P=0.029],病程长[RF(-)抗CCP抗体(-)50(20,126)个月,RF(-)抗CCP抗体(+)60(24,150)个月,RF(+)抗CCP抗体(+)89(35,179)个月,RF(+)抗CCP抗体(-)83(25,160)个月,H=22.001,P<0.01],关节肿胀数(SJC)[RF(-)抗CCP抗体(-)2(0,6),RF(-)抗CCP抗体(+)2(0,5),RF(+)抗CCP抗体(+)2(0,7),RF(+)抗CCP抗体(-)2(0,6),H=8.939,P=0.03]、关节触痛数多[RF(-)抗CCP抗体(-)3(0,8),RF(-)抗CCP抗体(+)2(0,6),RF(+)抗CCP抗体(+)3(1,9),RF(+)抗CCP抗体(-)2(0,8),H=11.341,P=0.01],晨僵时间长[RF(-)抗CCP抗体(-)30(0,60)min,RF(-)抗CCP抗体(+)20(0,60)min,RF(+)抗CCP抗体(+)30(10,60)min,RF(+)抗CCP抗体(-)30(10,60)min,H=13.32,P<0.01];同时RF+患者的ESR[RF(-)抗CCP抗体(-)17(9,38)mm/1 h,RF(-)抗CCP抗体(+)20(10,35)mm/1 h,RF(+)抗CCP抗体(+)26(14,45)mm/1 h,RF(+)抗CCP抗体(-)28(14,50)mm/1 h,H=37.084,P<0.01]及CRP[RF(-)抗CCP抗体(-)2.3(0.8,15.9)mg/L,RF(-)抗CCP抗体(+)2.7(0.7,12.1)mg/L,RF(+)抗CCP抗体(+)5.2(1.3,17.2)mg/L,RF(+Objective In general,patients with seropositive rheumatoid arthritis(RA)are considered to show an aggressive disease course.However,the relationship between the two subgroups in disease severity is controversial.Our study is aimed to compare the clinical characteristics and prognosis of double-seropositive and seronegative RA in China through a real-world large scale study.Methods RA patients who met the 1987 American College of Rheumatology(ACR)classification criteria or the 2010 ACR/European Anti-Rheumatism Alliance RA classification criteria,and who attended the 10 hospitals across the country from September 2015 to January 2020,were enrolled.According to the serological status,patients were divided into 4 subgroups[rheumatoid factor(RF)(-)anti-cyclic citrullinated peptide(CCP)antibody(-),RF(+),RF(+)anti-CCP antibody(+),anti-CCP antibody(+)]and compared the disease characteristics and treatment response.One-way analysis of variance was used for measurement data that conformed to normal distribution,Kruskal-Wallis H test was used for measurement data that did not conform to normal distribution;paired t test was used for comparison before and after treatment within the group if the data was normally distributed else paired rank sum test was used;χ^(2) test was used for count data.Results①A total of 2461 patients were included,including 1813 RF(+)anti-CCP antibody(+)patients(73.67%),129 RF(+)patients(5.24%),245 RF(-)anti-CCP antibody(-)patients(9.96%),74 anti-CCP antibody(+)patients(11.13%).②Regardless of the CCP status,RF(+)patients had an early age of onset[RF(-)anti-CCP antibody(-)(51±14)years old,anti-CCP antibody(+)(50±15)years old,RF(+)anti-CCP antibody(+)(48±14)years old,RF(+)(48±13)years old,F=3.003,P=0.029],longer disease duration[RF(-)anti-CCP antibody(-)50(20,126)months,anti-CCP antibody(+)60(24,150)months,RF(+)anti-CCP antibody(+)89(35,179)months,RF(+)83(25,160)months,H=22.001,P<0.01],more joint swelling counts(SJC)[RF(-)anti-CCP antibody(-)2(0,6),Anti-CCP antibody(+)2(0,5),RF(+)anti-CCP anti
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...